Crinetics Net Income Per E B T from 2010 to 2024

CRNX Stock  USD 58.78  1.23  2.05%   
Crinetics Pharmaceuticals Net Income Per E B T yearly trend continues to be fairly stable with very little volatility. Net Income Per E B T will likely drop to 1.08 in 2024. During the period from 2010 to 2024, Crinetics Pharmaceuticals Net Income Per E B T regression line of annual values had r-squared of  0.34 and arithmetic mean of  1.00. View All Fundamentals
 
Net Income Per E B T  
First Reported
2010-12-31
Previous Quarter
1.12
Current Value
1.08
Quarterly Volatility
0.04199227
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Crinetics Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Crinetics Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 14.1 M, Interest Income of 14.1 M or Depreciation And Amortization of 760.2 K, as well as many indicators such as Price To Sales Ratio of 918, Dividend Yield of 0.0 or PTB Ratio of 4.02. Crinetics financial statements analysis is a perfect complement when working with Crinetics Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Crinetics Pharmaceuticals Correlation against competitors.
For more information on how to buy Crinetics Stock please use our How to Invest in Crinetics Pharmaceuticals guide.

Latest Crinetics Pharmaceuticals' Net Income Per E B T Growth Pattern

Below is the plot of the Net Income Per E B T of Crinetics Pharmaceuticals over the last few years. It is Crinetics Pharmaceuticals' Net Income Per E B T historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Crinetics Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Net Income Per E B T10 Years Trend
Slightly volatile
   Net Income Per E B T   
       Timeline  

Crinetics Net Income Per E B T Regression Statistics

Arithmetic Mean1.00
Geometric Mean1.00
Coefficient Of Variation4.21
Mean Deviation0.03
Median0.98
Standard Deviation0.04
Sample Variance0
Range0.1442
R-Value0.58
Mean Square Error0
R-Squared0.34
Significance0.02
Slope0.01
Total Sum of Squares0.02

Crinetics Net Income Per E B T History

2024 1.08
2023 1.12
2020 0.99

About Crinetics Pharmaceuticals Financial Statements

Crinetics Pharmaceuticals investors use historical fundamental indicators, such as Crinetics Pharmaceuticals' Net Income Per E B T, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Crinetics Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Income Per E B T 1.12  1.08 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Crinetics Stock Analysis

When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.